Extrawell Pharmaceutical Holdings Limited (HKG:0858)
Hong Kong
· Delayed Price · Currency is HKD 0.0930
+0.0420 (82.35%)
Jun 24, 2025, 3:44 PM HKT
HKG:0858 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 59.75 | 59.1 | 72.58 | 73.93 | 78.8 | 77.58 | Upgrade
|
| Revenue Growth (YoY) | -12.93% | -18.57% | -1.82% | -6.19% | 1.57% | -13.04% | Upgrade
|
| Cost of Revenue | 34.05 | 30.32 | 41.43 | 36.37 | 36.24 | 34.67 | Upgrade
|
| Gross Profit | 25.7 | 28.78 | 31.14 | 37.56 | 42.57 | 42.92 | Upgrade
|
| Selling, General & Admin | 31.96 | 35.33 | 42.42 | 50.5 | 53.43 | 51 | Upgrade
|
| Operating Expenses | 31.96 | 35.33 | 42.42 | 50.5 | 53.43 | 51 | Upgrade
|
| Operating Income | -6.26 | -6.55 | -11.28 | -12.94 | -10.87 | -8.08 | Upgrade
|
| Interest Expense | -20.41 | -18.8 | -15.64 | -13.23 | -11.24 | -9.35 | Upgrade
|
| Interest & Investment Income | 5.57 | 5.67 | 2.99 | 1.08 | 5.17 | 12.81 | Upgrade
|
| Earnings From Equity Investments | -2.4 | -2.28 | -3.85 | -3.65 | -2.88 | -3.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.16 | -4.74 | -0.27 | -7.76 | 3.82 | -8.19 | Upgrade
|
| EBT Excluding Unusual Items | -25.67 | -26.69 | -28.05 | -36.5 | -16 | -15.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | 204.21 | -132.93 | 158.66 | 168.64 | -104.7 | 101.38 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.06 | - | 0.09 | Upgrade
|
| Other Unusual Items | 0.12 | 0.12 | 0.28 | 0.25 | 1.04 | - | Upgrade
|
| Pretax Income | 178.66 | -159.51 | 130.9 | 132.33 | -119.66 | 85.49 | Upgrade
|
| Income Tax Expense | 1.93 | 2.13 | 1.13 | 1.24 | - | -0.09 | Upgrade
|
| Earnings From Continuing Operations | 176.73 | -161.64 | 129.77 | 131.09 | -119.66 | 85.58 | Upgrade
|
| Net Income to Company | 176.73 | -161.64 | 129.77 | 131.09 | -119.66 | 85.58 | Upgrade
|
| Minority Interest in Earnings | -1.02 | -1.31 | -0.51 | -0.5 | -1.44 | -2.3 | Upgrade
|
| Net Income | 175.71 | -162.95 | 129.27 | 130.59 | -121.1 | 83.28 | Upgrade
|
| Net Income to Common | 175.71 | -162.95 | 129.27 | 130.59 | -121.1 | 83.28 | Upgrade
|
| Net Income Growth | - | - | -1.01% | - | - | 30.06% | Upgrade
|
| Shares Outstanding (Basic) | 2,390 | 2,390 | 2,390 | 2,390 | 2,390 | 2,390 | Upgrade
|
| Shares Outstanding (Diluted) | 2,840 | 2,390 | 3,290 | 3,290 | 2,390 | 3,290 | Upgrade
|
| Shares Change (YoY) | 18.83% | -27.36% | - | 37.66% | -27.36% | - | Upgrade
|
| EPS (Basic) | 0.07 | -0.07 | 0.05 | 0.05 | -0.05 | 0.03 | Upgrade
|
| EPS (Diluted) | 0.07 | -0.07 | 0.04 | 0.04 | -0.05 | 0.03 | Upgrade
|
| EPS Growth | - | - | 0.78% | - | - | 28.87% | Upgrade
|
| Free Cash Flow | 1.61 | -4.89 | -5.44 | -11.39 | -1.57 | -13.41 | Upgrade
|
| Free Cash Flow Per Share | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | Upgrade
|
| Gross Margin | 43.01% | 48.70% | 42.91% | 50.80% | 54.02% | 55.32% | Upgrade
|
| Operating Margin | -10.48% | -11.09% | -15.54% | -17.51% | -13.79% | -10.42% | Upgrade
|
| Profit Margin | 294.08% | -275.73% | 178.11% | 176.65% | -153.67% | 107.34% | Upgrade
|
| Free Cash Flow Margin | 2.69% | -8.28% | -7.49% | -15.41% | -2.00% | -17.29% | Upgrade
|
| EBITDA | 0.63 | 0.73 | -4.63 | -6.4 | -4.9 | -2.19 | Upgrade
|
| EBITDA Margin | 1.05% | 1.24% | -6.38% | -8.66% | -6.22% | -2.82% | Upgrade
|
| D&A For EBITDA | 6.89 | 7.29 | 6.65 | 6.54 | 5.97 | 5.89 | Upgrade
|
| EBIT | -6.26 | -6.55 | -11.28 | -12.94 | -10.87 | -8.08 | Upgrade
|
| EBIT Margin | -10.48% | -11.09% | -15.54% | -17.51% | -13.79% | -10.42% | Upgrade
|
| Effective Tax Rate | 1.08% | - | 0.86% | 0.94% | - | - | Upgrade
|
Updated Dec 17, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.